Literature DB >> 3539456

Evaluation of the indirect immunofluorescence assay as a confirmatory test for detecting antibodies to the human immunodeficiency virus.

T M McHugh, D P Stites, C H Casavant, J R Carlson, J Yee, P A McVay, M P Busch, J A Levy.   

Abstract

One hundred and eighty-four serum specimens were assayed for antibodies to the human immunodeficiency virus. All specimens were screened with a commercial enzyme immunoassay and confirmed by two indirect immunofluorescence assays. Sera were also assayed by Western blot. Results from sera of 48 healthy heterosexual volunteers were all negative by EIA, IFA, and Western blot. Sera from 50 healthy homosexual men negative by EIA were also negative by IFA and Western blot. Sixty-two patients with persistent generalized lymphadenopathy or newly diagnosed AIDS all were positive by EIA, IFA, and Western blot. Of 24 sera from patients with autoantibodies, with no evidence of AIDS-related diseases, five appeared to be false-positive by EIA, since they were nonreactive by IFA and Western blot. In addition, three other samples contained both autoantibodies and human immunodeficiency virus antibodies. False-positive results were observed in both the EIA and IFA with monoclonal antibodies directed toward the MHC class II antigens DQ and DR. The reactivity of these antibodies could not be distinguished from positive patients' sera, in either EIA or IFA. We conclude that in general indirect immunofluorescence performed well as a confirmatory test after screening by enzyme immunoassay for human immunodeficiency virus antibodies.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 3539456

Source DB:  PubMed          Journal:  Diagn Immunol        ISSN: 0735-3111


  5 in total

1.  Tumor necrosis factor alpha selectively sensitizes human immunodeficiency virus-infected cells to heat and radiation.

Authors:  G H Wong; T McHugh; R Weber; D V Goeddel
Journal:  Proc Natl Acad Sci U S A       Date:  1991-05-15       Impact factor: 11.205

2.  Indirect immunofluorescence test performance and questionnaire results from the Centers for Disease Control Model Performance Evaluation Program for human immunodeficiency virus type 1 testing.

Authors:  R N Taylor; T L Hearn; W O Schalla; R O Valdiserri
Journal:  J Clin Microbiol       Date:  1990-08       Impact factor: 5.948

3.  Performance and reliability of five commercial enzyme-linked immunosorbent assay kits in screening for anti-human immunodeficiency virus antibody in high-risk subjects.

Authors:  G Ozanne; M Fauvel
Journal:  J Clin Microbiol       Date:  1988-08       Impact factor: 5.948

4.  Immunofluorescence assay for human immunodeficiency virus antibody: investigation of cell fixation for virus inactivation and antigen preservation.

Authors:  M Fauvel; G Ozanne
Journal:  J Clin Microbiol       Date:  1989-08       Impact factor: 5.948

5.  Advantages of a human immunodeficiency virus type 1 (HIV-1) persistently infected HeLa T4+ cell line for HIV-1 indirect immunofluorescence serology.

Authors:  B Forghani; J W Hurst; C S Chan
Journal:  J Clin Microbiol       Date:  1991-10       Impact factor: 5.948

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.